

Product Data Sheet

Mometasone furoate

 Cat. No.:
 HY-13693

 CAS No.:
 83919-23-7

 Molecular Formula:
 $C_{27}H_{30}Cl_2O_6$

 Molecular Weight:
 521.43

Target: Glucocorticoid Receptor

Pathway: Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Storage: Powder -20°C 3 years

 $\label{eq:continuous} 4^{\circ}\text{C} \qquad \text{2 years}$ In solvent $\label{eq:continuous} -80^{\circ}\text{C} \qquad \text{2 years}$

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (95.89 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9178 mL	9.5890 mL	19.1780 mL
	5 mM	0.3836 mL	1.9178 mL	3.8356 mL
	10 mM	0.1918 mL	0.9589 mL	1.9178 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity.

Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo^[1]

IC₅₀ & Target IC50: Glucocorticoid Receptor

Mometasone furoate binds to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus^[1].

?Mometasone furoate (0.1-10 μ M; 2h before LPS stimulation) strongly inhibits LPS-stimulated nitrite production in a concentration-dependent manner in J774 macrophages, The IC50 value is 0.00024 μ M for Mometasone?furoate in J774 cells

In Vitro

[1]

?Mometasone furoate (0.1-10 μ M; 2h before LPS stimulation) is more potent than DEX, it significantly inhibits iNOS expression at a 0.01 μ M concentration whereas Dex became active at 0.1 μ M. Additionally, the inhibition of cox-2 protein expression at 0.01 μ M is 79% for Mometasone?furoate and 39% for Dex^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Am Chem Soc. 2021 Oct 14.
- Hematology. 2018 Sep;23(8):478-485.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Maria Galuppo, et al. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res. 2015 Sep;99:316-28

[2]. https://go.drugbank.com/drugs/DB14512

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA